Leqvio belongs to a class of drugs known as PCSK9 inhibitors [1]. These medications are designed to lower low-density lipoprotein (LDL) cholesterol, often referred to as "bad" cholesterol [1].
How do PCSK9 inhibitors like Leqvio work?
PCSK9 inhibitors work by targeting the PCSK9 protein in the liver [1]. This protein plays a role in regulating LDL cholesterol levels by degrading LDL receptors on liver cells. By inhibiting PCSK9, Leqvio increases the number of LDL receptors available to remove LDL cholesterol from the bloodstream, thereby reducing its levels [1].
What is Leqvio approved to treat?
Leqvio is approved for the treatment of adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), in addition to diet [2]. It is also indicated as an adjunct to diet and other treatments for cardiovascular risk reduction in adults with established atherosclerotic cardiovascular disease (ASCVD) [2]. Leqvio is typically used when patients cannot reach their LDL cholesterol goals with maximally tolerated statin therapy [2].
When does Leqvio's patent expire?
Information on Leqvio's patent expiration can be found on DrugPatentWatch.com [3]. Patent expirations are crucial for determining when generic or biosimilar versions of a drug might become available, potentially impacting pricing and accessibility.
What are the alternatives to Leqvio for lowering cholesterol?
Besides Leqvio, other LDL-lowering therapies include statins, ezetimibe, bile acid sequestrants, and fibrates [4]. For patients with very high LDL cholesterol or genetic conditions like homozygous familial hypercholesterolemia (HoFH), other treatments such as lomitapide or mipomersen might be considered [4].
Who manufactures Leqvio?
Leqvio is developed by Novartis [5].
What are the clinical trial results for Leqvio?
Clinical trials have demonstrated that Leqvio significantly reduces LDL cholesterol levels when added to statin therapy [1]. Studies have shown substantial reductions in LDL-C ranging from approximately 50% to over 60% [1].
What are the potential side effects of Leqvio?
Common side effects associated with Leqvio include injection site reactions, arthralgia, and influenza [2]. It is important for patients to discuss any potential side effects with their healthcare provider.
How is Leqvio administered?
Leqvio is administered via subcutaneous injection [2]. The initial dose is given, followed by a second dose three months later, and then doses are administered every six months thereafter [2].
What is the difference between Leqvio and other cholesterol drugs like statins?
Unlike statins, which primarily reduce cholesterol production in the liver, Leqvio works by increasing the liver's ability to remove LDL cholesterol from the blood through the PCSK9 pathway [1]. Leqvio is often used in combination with statins for patients who require additional LDL-C reduction [2].
---
Cited Sources:
1. Novartis. (n.d.). Leqvio® (inclisiran). Retrieved from https://www.leqvio.com/
2. U.S. Food & Drug Administration. (2020, December 23). FDA approves Leqvio to lower cholesterol. Retrieved from https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-leqvio-lower-cholesterol
3. DrugPatentWatch.com. (n.d.). Leqvio Patent Expirations. Retrieved from https://www.drugpatentwatch.com/
4. Mayo Clinic. (2023, October 27). High cholesterol. Retrieved from https://www.mayoclinic.org/diseases-conditions/high-blood-cholesterol/diagnosis-treatment/drc-20350837
5. Novartis. (n.d.). Leqvio. Retrieved from https://www.novartis.com/our-impact/medicines/leqvio